Physician profile

John Ryan

Sports Medicine (Orthopaedic Surgery) · Warren, MI

NPI 1023000882

$12,383.66

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$479.86
Food and Beverage$66.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pinnacle, INC $10,048.95 2020-2024
Arthrex, INC. $1,893.68 2021-2022
Djo, LLC $182.14 2022
Zimmer Biomet Holdings, INC. $94.34 2019
Smith+Nephew, INC. $63.57 2022
Si-Bone, INC. $31.53 2024
Nevro Corp. $19.76 2024 Senza
Linvatec Corporation $19.66 2021
Orthofix Medical, INC. $15.59 2023 Physio-Stim, Spinal-Stim
Kowa Pharmaceuticals America, INC. $14.44 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John Ryan

$12,383.66

in general payments reported 2019-2025

Years
2019-2024
Top company
Pinnacle, INC

https://glasscript.com/doctor/182731/john-ryan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.